197 related articles for article (PubMed ID: 33073549)
1. Ligand Density Controls C-Type Lectin-Like Molecule-1 Receptor-Specific Uptake of Polymer Nanoparticles.
Ackun-Farmmer MA; Alatise KL; Cross G; Benoit DSW
Adv Biosyst; 2020 Nov; 4(11):e2000172. PubMed ID: 33073549
[TBL] [Abstract][Full Text] [Related]
2. Advancing Bone-Targeted Drug Delivery: Leveraging Biological Factors and Nanoparticle Designs to Improve Therapeutic Efficacy.
Xiao B; Ackun-Farmmer MA; Adjei-Sowah E; Liu Y; Chandrasiri I; Benoit DSW
ACS Biomater Sci Eng; 2024 Apr; 10(4):2224-2234. PubMed ID: 38537162
[TBL] [Abstract][Full Text] [Related]
3. Characterization of high-affinity peptides and their feasibility for use in nanotherapeutics targeting leukemia stem cells.
Zhang H; Luo J; Li Y; Henderson PT; Wang Y; Wachsmann-Hogiu S; Zhao W; Lam KS; Pan CX
Nanomedicine; 2012 Oct; 8(7):1116-24. PubMed ID: 22197725
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel (DTX)-loaded polydopamine-modified TPGS-PLA nanoparticles as a targeted drug delivery system for the treatment of liver cancer.
Zhu D; Tao W; Zhang H; Liu G; Wang T; Zhang L; Zeng X; Mei L
Acta Biomater; 2016 Jan; 30():144-154. PubMed ID: 26602819
[TBL] [Abstract][Full Text] [Related]
5. Assessing potential peptide targeting ligands by quantification of cellular adhesion of model nanoparticles under flow conditions.
Broda E; Mickler FM; Lächelt U; Morys S; Wagner E; Bräuchle C
J Control Release; 2015 Sep; 213():79-85. PubMed ID: 26134072
[TBL] [Abstract][Full Text] [Related]
6. Differential uptake of nanoparticles by endothelial cells through polyelectrolytes with affinity for caveolae.
Voigt J; Christensen J; Shastri VP
Proc Natl Acad Sci U S A; 2014 Feb; 111(8):2942-7. PubMed ID: 24516167
[TBL] [Abstract][Full Text] [Related]
7. Dual-Ligand Modified Polymer-Lipid Hybrid Nanoparticles for Docetaxel Targeting Delivery to Her2/neu Overexpressed Human Breast Cancer Cells.
Yang Z; Tang W; Luo X; Zhang X; Zhang C; Li H; Gao D; Luo H; Jiang Q; Liu J
J Biomed Nanotechnol; 2015 Aug; 11(8):1401-17. PubMed ID: 26295141
[TBL] [Abstract][Full Text] [Related]
8. The Weak Link: Optimization of the Ligand-Nanoparticle Interface To Enhance Cancer Cell Targeting by Polymer Micelles.
Wang J; Dzuricky M; Chilkoti A
Nano Lett; 2017 Oct; 17(10):5995-6005. PubMed ID: 28853896
[TBL] [Abstract][Full Text] [Related]
9. Fracture-Targeted Delivery of β-Catenin Agonists via Peptide-Functionalized Nanoparticles Augments Fracture Healing.
Wang Y; Newman MR; Ackun-Farmmer M; Baranello MP; Sheu TJ; Puzas JE; Benoit DSW
ACS Nano; 2017 Sep; 11(9):9445-9458. PubMed ID: 28881139
[TBL] [Abstract][Full Text] [Related]
10. Effects of poly(ethylene glycol) grafting density on the tumor targeting efficacy of nanoparticles with ligand modification.
Zhang S; Tang C; Yin C
Drug Deliv; 2015 Feb; 22(2):182-90. PubMed ID: 24215373
[TBL] [Abstract][Full Text] [Related]
11. The effects of ligand valency and density on the targeting ability of multivalent nanoparticles based on negatively charged chitosan nanoparticles.
Cao J; Zhang Y; Wu Y; Wu J; Wang W; Wu Q; Yuan Z
Colloids Surf B Biointerfaces; 2018 Jan; 161():508-518. PubMed ID: 29128837
[TBL] [Abstract][Full Text] [Related]
12. Controlling ligand surface density optimizes nanoparticle binding to ICAM-1.
Fakhari A; Baoum A; Siahaan TJ; Le KB; Berkland C
J Pharm Sci; 2011 Mar; 100(3):1045-56. PubMed ID: 20922813
[TBL] [Abstract][Full Text] [Related]
13. Ligand-Modified Erythrocyte Membrane-Cloaked Metal-Organic Framework Nanoparticles for Targeted Antitumor Therapy.
Lin Y; Zhong Y; Chen Y; Li L; Chen G; Zhang J; Li P; Zhou C; Sun Y; Ma Y; Xie Z; Liao Q
Mol Pharm; 2020 Sep; 17(9):3328-3341. PubMed ID: 32804508
[TBL] [Abstract][Full Text] [Related]
14. Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: a comparative study.
Cruz LJ; Rosalia RA; Kleinovink JW; Rueda F; Löwik CW; Ossendorp F
J Control Release; 2014 Oct; 192():209-18. PubMed ID: 25068703
[TBL] [Abstract][Full Text] [Related]
15. Enhanced uptake and transport of PLGA-modified nanoparticles in cervical cancer.
Sims LB; Curtis LT; Frieboes HB; Steinbach-Rankins JM
J Nanobiotechnology; 2016 Apr; 14():33. PubMed ID: 27102372
[TBL] [Abstract][Full Text] [Related]
16. Biodegradable polymeric nanoparticles administered in the cerebrospinal fluid: Brain biodistribution, preferential internalization in microglia and implications for cell-selective drug release.
Peviani M; Capasso Palmiero U; Cecere F; Milazzo R; Moscatelli D; Biffi A
Biomaterials; 2019 Jul; 209():25-40. PubMed ID: 31026609
[TBL] [Abstract][Full Text] [Related]
17. Modeling of nanoparticle transport through the female reproductive tract for the treatment of infectious diseases.
Sims LB; Miller HA; Halwes ME; Steinbach-Rankins JM; Frieboes HB
Eur J Pharm Biopharm; 2019 May; 138():37-47. PubMed ID: 30195726
[TBL] [Abstract][Full Text] [Related]
18. Size-dependent internalisation of folate-decorated nanoparticles via the pathways of clathrin and caveolae-mediated endocytosis in ARPE-19 cells.
Langston Suen WL; Chau Y
J Pharm Pharmacol; 2014 Apr; 66(4):564-73. PubMed ID: 24635558
[TBL] [Abstract][Full Text] [Related]
19. Quantitative Study of the Interaction of Multivalent Ligand-Modified Nanoparticles with Breast Cancer Cells with Tunable Receptor Density.
Wang J; Min J; Eghtesadi SA; Kane RS; Chilkoti A
ACS Nano; 2020 Jan; 14(1):372-383. PubMed ID: 31899613
[TBL] [Abstract][Full Text] [Related]
20. In vitro evaluation of dendrimer-polymer hybrid nanoparticles on their controlled cellular targeting kinetics.
Sunoqrot S; Liu Y; Kim DH; Hong S
Mol Pharm; 2013 Jun; 10(6):2157-66. PubMed ID: 23234605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
